Copiktra
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.copiktra.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Copiktra
Secura Care offers COPIKTRA® (duvelisib) capsules, a prescription medication designed for adults with relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two prior therapies. The company provides essential patient resources, including medication guides, safety information, and support services, emphasizing the importance of monitoring for potential side effects. Secura Care's primary clients are adult patients suffering from relapsed CLL/SLL seeking effective treatment options. Additionally, the company supports healthcare providers with crucial prescribing information and safety guidelines.Explore more
Popular SearchesCopiktraSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Copiktra your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Copiktra
Product Launch: Get notified when Copiktra launches new products
Copiktra, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Copiktra had a recent Job posting/layoffs
Check out if Copiktra is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Copiktra recently announced quarterly report
Funding: Get notified immidiatlly once Copiktra has new funding data
Check if Copiktra has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Copiktra as Masked Content
Find 3 more new buyers
Compare Similar Companies to Copiktra
Compare insights from companies similar to Copiktra, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Copiktra
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Copiktra is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Copiktra is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Copiktra.
Copiktra Tech Stack
A closer look at the technologies used by Copiktra
See more technologies
Copiktra News & Media
Secura Bio Announces NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for Cutaneous T-Cell Lymphoma (CTCL), Including Mycosis Fungoides and Sézary Syndrome
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that duvelisib (COPIKTRA®) was added by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a NCCN Category 2A treatment option for mycosis fungoides / Sézary Syndrome (MFSS).Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma
Interim data from the first phase 3 study of a PI3K inhibitor to treat relapsed or refractory nodal T-follicular helper cell lymphoma (nTFHL) anticipated in early-2027 Interim data from the first phase 3 study of a PI3K inhibitor to treat relapsed or refractory nodal T-follicular helper cell lymphoma (nTFHL) anticipated in early-2027New Combination Data of Secura Bio’s COPIKTRA® (duvelisib) Presented at the 2024 American Society of Hematology Meeting
Dr. Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell lymphoma or cutaneous T-cell lymphomaSecura Bio Presented New Data from its Phase 2 PRIMO Trial of Copiktra® (Duvelisib) in Relapsed or Refractory Peripheral T-cell Lymphoma and Announced Plans for its Phase 3 TERZO Trial at the 2024 American Society of Hematology Meeting
Data from the Phase 2 PRIMO trial in 123 patients showed an overall response rate (ORR) of 48%, a complete response (CR) rate of 33%, and a median duration of response (DOR) of 7.89 months
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Copiktra
Sign Up For FreeTo access detailed company insights
Secura Care offers COPIKTRA® (duvelisib) capsules, a prescription medication designed for adults with relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two prior therapies. The company provides essential patient resources, including medication guides, safety information, and support services... Read More
